Edwards Lifesciences balance sheet

At the end of fiscal 2025, Edwards Lifesciences had total assets of $13.70bn, total liabilities of $3.36bn and shareholders' equity of $10.34bn. It held $2.94bn in cash against $598m of debt.

Balance sheet

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Edwards Lifesciences: balance sheet, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash and equivalents	0.3	0.4	0.2	0.3	0.4	0.7	0.7	0.9	0.8	0.7	1.2	1.2	0.9	0.8	1.1	3.0	2.9	2.9
Receivables	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.4	0.5	0.5	0.5	0.6	0.6	0.8	0.6	0.7	0.8
Inventory	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.4	0.6	0.6	0.6	0.8	0.7	0.9	0.9	1.1	1.1	1.1
Total current assets	0.9	1.0	1.2	1.3	1.7	2.2	2.0	2.2	2.5	2.3	3.0	3.1	3.2	3.1	4.0	6.3	6.7	6.8
Goodwill	0.3	0.3	0.3	0.4	0.4	0.4	0.6	0.6	1.1	1.1	1.2	1.2	1.2	1.1	1.1	1.8	1.8	2.0
Total assets	1.6	1.8	2.0	2.2	2.7	3.5	4.1	4.5	5.7	5.3	6.5	7.2	8.5	8.3	9.4	13.1	13.7	13.9
Accounts payable	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Total current liabilities	0.3	0.3	0.3	0.3	0.3	0.4	0.5	0.5	1.4	0.9	0.9	0.9	1.0	1.0	1.2	1.5	1.8	1.5
Short-term debt	—	—	—	—	—	—	—	0.0	0.6	0.0	—	—	—	—	—	—	—	—
Long-term debt	0.1	—	—	0.2	0.6	0.6	0.6	0.8	0.4	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
Total debt	0.1	0.2	0.2	0.2	0.6	0.6	0.6	0.8	1.0	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
Total liabilities	—	—	—	—	—	—	—	—	—	—	—	2.7	2.7	2.5	2.6	3.0	3.4	3.1
Shareholders' equity	1.2	1.3	1.3	1.5	1.5	2.2	2.5	2.6	3.0	3.1	4.1	4.6	5.8	5.8	6.7	10.0	10.3	10.6
Shares outstanding	—	690m	685m	686m	656m	647m	646m	635m	629m	623m	627m	624m	624m	608m	601m	589m	581m	577m

US$ billions unless shown otherwise. Fiscal quarters.

Edwards Lifesciences: balance sheet, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Receivables	0.7	0.6	0.7	0.7	0.7	0.7	0.8	0.8
Inventory	1.1	1.1	1.1	1.1	1.1	1.1	1.1	1.1
Total current assets	6.7	6.3	6.2	6.6	6.4	6.7	6.2	6.8
Goodwill	1.6	1.8	1.8	1.8	1.8	1.8	1.8	2.0
Total assets	13.0	13.1	13.0	13.5	13.3	13.7	13.3	13.9
Accounts payable	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Total current liabilities	1.9	1.5	1.4	1.4	1.6	1.8	1.4	1.5
Long-term debt	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
Total debt	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.6
Total liabilities	3.4	3.0	2.8	2.9	3.1	3.4	3.0	3.1
Shareholders' equity	9.5	10.0	10.1	10.5	10.2	10.3	10.3	10.6
Shares outstanding	590m	589m	586m	588m	581m	581m	577m	577m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: EW vs STE EW vs RMD BLCO vs EW EW vs ZBH

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Edwards Lifesciences's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Edwards Lifesciences.